Sara J Hardy

Dr. Sara J Hardy


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
SHSara J Hardy
Sara J Hardy
SBSanjukta Bandyopadhyay
Sanjukta Bandyopadhyay
HYHongmei Yang
Hongmei Yang
AWAnnalynn Williams
Annalynn Williams
AGAbdi Gudina
Abdi Gudina
MMMichael T. Milano
Michael T. Milano
Objectives: Head and neck cancer is a common malignancy frequently treated with chemotherapy and radiotherapy. Studies have shown an increased risk of stroke with the receipt of radiotherapy, but data on stroke-related mortality are limited, particularly in the modern era. Evaluating stroke mortality related to radiotherapy is vital given the curative nature of head and neck cancer treatment and the need to understand the risk of severe stroke in this population.Methods: We analyzed the risk of stroke death among 122,362 patients (83,651 patients who received radiation and 38,711 patients who did not) with squamous cell carcinoma of the head and neck (HNSCC) diagnosed between 1973 and 2015 in the SEER database. Patients in radiation vs. no radiation groups were matched using propensity scores. Our primary hypothesis was that radiotherapy would increase the hazard of death from stroke. We also examined other factors impacting the hazard of stroke death, including whether radiotherapy was performed during the modern era when IMRT and modern stroke care were available as well as increased HPV-mediated cancers of the head and neck. We hypothesized that the hazard of stroke death would be less in the modern era.Results: There was an increased hazard of stroke-related death in the group receiving radiation therapy (HR 1.203, p = 0.006); however, this was a very small absolute increase, and the cumulative incidence function of stroke death was significantly reduced in the modern era (p < 0.001), cohorts with chemotherapy (p=0.003), males (p=0.002), younger cohorts (p<0.001) and subsites other than nasopharynx (p=0.025).Conclusions: While radiotherapy for head and neck cancer increases the hazard of stroke death, this is reduced in the modern era and remains a very small absolute risk.

23 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
SHSara J Hardy
Sara J Hardy
AFAlan Finkelstein
Alan Finkelstein
MMMichael T Milano
Michael T Milano
GSGiovanni Schifitto
Giovanni Schifitto
HSHongying Sun
Hongying Sun
MJMichelle Janelsins
Michelle Janelsins
Background: Although data are limited, difficulty in social cognition occurs in up to 83% of patients with brain tumors. It is unknown whether cranial radiation therapy (RT) dose to the amygdala–orbitofrontal network can impact social cognition. Methods: We prospectively enrolled 51 patients with low-grade and benign brain tumors planned for cranial RT. We assessed longitudinal changes on an emotion recognition task (ERT) that measures the ability to recognize emotional states by displaying faces expressing six basic emotions and their association with the RT dose to the amygdala–orbitofrontal network. ERT outcomes included the median time to choose a response (ERTOMDRT) or correct response (ERTOMDCRT) and total correct responses (ERTHH). Results: The RT dose to the amygdala–orbitofrontal network was significantly associated with longer median response times on the ERT. Increases in median response times occurred at lower doses than decreases in total correct responses. The medial orbitofrontal cortex was the most important variable on regression trees predicting change in the ERTOMDCRT. Discussion: This is, to our knowledge, the first study to show that off-target RT dose to the amygdala–orbitofrontal network is associated with performance on a social cognition task, a facet of cognition that has previously not been mechanistically studied after cranial RT.

13 April 2022 in Nursing Research
Verified
Journal Article
Closed access
AKAmber S. Kleckner
Amber S. Kleckner
IKIan R. Kleckner
Ian R. Kleckner
ECEva Culakova
Eva Culakova
AWAndrew Wojtovich
Andrew Wojtovich
NKN. Jennifer Klinedinst
N. Jennifer Klinedinst
LPLuke Joseph Peppone
Luke Joseph Peppone
Background: Cancer-related fatigue is a prevalent, debilitating, and persistent condition. Mitochondrial dysfunction is a putative contributor to cancer-related fatigue, but relationships between mitochondrial function and cancer-related fatigue are not well understood. Objectives: We investigated the relationships between mitochondrial DNA (mtDNA) gene expression and cancer-related fatigue, as well as the effects of fish and soybean oil supplementation on these relationships. Methods: A secondary analysis was performed on data from a randomized controlled trial of breast cancer survivors 4–36 months posttreatment with moderate–severe cancer-related fatigue. Participants were randomized to take 6 g fish oil, 6 g soybean oil, or 3 g each daily for 6 weeks. At pre- and postintervention, participants completed the Functional Assessment of Chronic Illness Therapy–Fatigue questionnaire and provided whole blood for assessment of mtDNA gene expression. The expression of 12 protein-encoding genes was reduced to a single dimension using principal component analysis for use in regression analysis. Relationships between mtDNA expression and cancer-related fatigue were assessed using linear regression. Results: Among 68 participants, cancer-related fatigue improved and expression of all mtDNA genes decreased over 6 weeks with no effect of treatment group on either outcome. Participants with lower baseline mtDNA gene expression had greater improvements in cancer-related fatigue. No significant associations were observed between mtDNA gene expression and cancer-related fatigue at baseline or changes in mtDNA gene expression and changes in cancer-related fatigue. Discussion: Data from this exploratory study add to the growing literature that mitochondrial dysfunction may contribute to the etiology and pathophysiology of cancer-related fatigue.

15 February 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
SHSara J Hardy
Sara J Hardy
AFAlan J Finkelstein
Alan J Finkelstein
MTMadalina Tivarus
Madalina Tivarus
ECEva Culakova
Eva Culakova
NMNimish Mohile
Nimish Mohile
MJM C Janelsins-Benton
M C Janelsins-Benton
Introduction Radiation-induced cognitive decline (RICD) occurs in 50%–90% of adult patients 6 months post-treatment. In patients with low-grade and benign tumours with long expected survival, this is of paramount importance. Despite advances in radiation therapy (RT) treatment delivery, better understanding of structures important for RICD is necessary to improve cognitive outcomes. We hypothesise that RT may affect network topology and microstructural integrity on MRI prior to any gross anatomical or apparent cognitive changes. In this longitudinal cohort study, we aim to determine the effects of RT on brain structural and functional integrity and cognition. Methods and analysis This study will enroll patients with benign and low-grade brain tumours receiving partial brain radiotherapy. Patients will receive either hypofractionated (>2 Gy/fraction) or conventionally fractionated (1.8–2 Gy/fraction) RT. All participants will be followed for 12 months, with MRIs conducted pre-RT and 6-month and 12 month post-RT, along with a battery of neurocognitive tests and questionnaires. The study was initiated in late 2018 and will continue enrolling through 2024 with final follow-ups completing in 2025. The neurocognitive battery assesses visual and verbal memory, attention, executive function, processing speed and emotional cognition. MRI protocols incorporate diffusion tensor imaging and resting state fMRI to assess structural connectivity and functional connectivity, respectively. We will estimate the association between radiation dose, imaging metrics and cognitive outcomes. Ethics and dissemination This study has been approved by the Research Subjects Review Board at the University of Rochester (STUDY00001512: Cognitive changes in patients receiving partial brain radiation). All results will be published in peer-reviewed journals and at scientific conferences. Trial registration number ClinicalTrials.gov NCT04390906.

20 March 2024 in Lung Cancer
Verified
Journal Article
Closed access
AGAbdi T. Gudina
Abdi T. Gudina
CKCharles Kamen
Charles Kamen
SHSara J Hardy
Sara J Hardy
LKLee Kehoe
Lee Kehoe
ECEva Culakova
Eva Culakova
ACAna-Paula Cupertino
Ana-Paula Cupertino

24 August 2021
Verified
Book Chapter
Closed access
PDF file
PLPo-Ju Lin
Po-Ju Lin
EBElizabeth K. Belcher
Elizabeth K. Belcher
NGNikesha J. Gilmore
Nikesha J. Gilmore
SHSara J Hardy
Sara J Hardy
HXHuiwen Xu
Huiwen Xu
KMKaren M. Mustian
Karen M. Mustian